Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: A French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study

Journal of Clinical Oncology

Volumn 32, Issue 31, 2014, Pages 3520-3526

  Guimbaud, Rosine ^a   Louvet, Christophe ^b   Ries, Pauline ^g   Ychou, Marc ^h   Maillard, Emilie ⁱ   André, Thierry ^c   Gornet, Jean Marc ^d   Aparicio, Thomas ^k   Nguyen, Suzanne ^l   Azzedine, Ahmed ^l   Etienne, Pierre Luc ^m   Boucher, Eveline ⁿ   Rebischung, Christine ^o   Hammel, Pascal ^e   Rougier, Philippe ^f   Bedenne, Laurent ^j   Bouché, Olivier ^p  

^a CHU RANGUEIL   (France)

^b Institut Mutualiste   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e BEAUJON HOSPITAL   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h CENTRE VAL D AURELLE   (France)

ⁱ Fédération Francophone de Cancérologie Digestive ^*  (France)

^j DIJON UNIVERSITY HOSPITAL   (France)

^k AVICENNE HOSPITAL   (France)

^l HÔPITAL DU BOCAGE   (France)

^m Clinique Armoricaine   (France)

ⁿ CENTRE EUGÈNE MARQUIS   (France)

^o HÔPITAL MICHALLON   (France)

^p SERVICE DE DERMATOLOGIE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENERAL CONDITION DETERIORATION; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; SUDDEN DEATH; TIME TO TREATMENT; TREATMENT RESPONSE; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; FRANCE; MIDDLE AGED; PATHOLOGY; STOMACH NEOPLASMS; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DEOXYCYTIDINE; EPIRUBICIN; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; FRANCE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84911864613     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.1011     Document Type: Article

References (24)

1. Wagner AD, Grothe W, Haerting J, et al: Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909, 2006
2. Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46, 2008
3. Al-Batran SE, Hartmann JT, Probst S, et al: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435-1442, 2008
4. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24:4991-4997, 2006
5. Kang JH, Lee SI, Lim do H, et al: Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513-1518, 2012
6. Ford H, Marshall A, Bridgewater JA, et al: Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): An open-label, phase 3 randomised controlled trial. Lancet Oncol 15:78-86, 2014
7. Thuss-Patience PC, Kretzschmar A, Bichev D, et al: Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer: A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47:2306-2314, 2011
8. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
9. Waddell T, Chau I, Cunningham D, et al: Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, openlabel phase 3 trial. Lancet Oncol 14:481-489, 2013
10. Lordick F, Kang YK, Chung HC, et al: Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol 14:490-499, 2013
11. Ohtsu A, Shah MA, Van Cutsem E, et al: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968-3976, 2011
12. Park SC, Chun HJ: Chemotherapy for advanced gastric cancer: Review and update of current practices. Gut Liver 7:385-393, 2013
13. Bouché O, Raoul JL, Bonnetain F, et al: Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 22:4319-4328, 2004
14. Dank M, Zaluski J, Barone C, et al: Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19:1450-1457, 2008
15. Qi WX, Shen Z, Lin F, et al: Overall survival benefits for irinotecan-containing regimens as firstline treatment for advanced gastric cancer: An updated meta-analysis of ten randomized controlled trials. Int J Cancer 132:E66-E73, 2013
16. Curran D, Pozzo C, Zaluski J, et al: Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: Results of a randomised phase III trial. Qual Life Res 18:853-861, 2009
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
18. Cho EK, Lee WK, Im SA, et al: A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer. Oncology 68:333-340, 2005
19. Vickery CW, Blazeby JM, Conroy T, et al: Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. Eur J Cancer 37:966-971, 2001
20. Guimbaud R, Bouché O, Rebischung C, et al: Planned interim analysis of the intergroup FFCD-GERCOR-FNCLCC-AERO phase III study comparing two sequences of chemotherapy in locally advanced or metastatic gastric cancers. J Clin Oncol 27:210s, 2009 (suppl 15s; abstr 4533)
21. Boku N, Yamamoto S, Fukuda H, et al: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study. Lancet Oncol 10:1063-1069, 2009
22. Wang DL, Gu DY, Huang HY, et al: Irinotecaninvolved regimens for advanced gastric cancer: A pooled-analysis of clinical trials. World J Gastroenterol 16:5889-5894, 2010
23. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Oba K, Paoletti X, et al: Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. Eur J Cancer 49:1565-1577, 2013
24. Enzinger PC, Burtness B, Hollis D, et al: CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 28:302s, 2010 (suppl 15s; abstr 4006)